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Objectives The RESOLUTE US (R-US) trial is a prospective, observational study designed to evaluate the clinical effective-
ness of the Resolute zotarolimus-eluting stent (R-ZES) in a U.S. population.
Background The R-ZES releases zotarolimus over a 6-month period in order to achieve optimal clinical effectiveness and
safety.
Methods The R-US trial recruited patients with de novo native coronary lesions suitable for 1- or 2-vessel treatment with
stents from 2.25 to 4.0 mm in diameter. In the main analysis cohort (2.5- to 3.5-mm stents and single-lesion
treatment), the primary endpoint was 12-month target lesion failure (TLF) defined as the composite of cardiac
death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR), compared with data from
Endeavor zotarolimus-eluting stent (E-ZES) trials, adjusting for baseline covariates through propensity scores.
Results Overall, 1,402 patients were enrolled with a mean reference vessel diameter of 2.59  0.47 mm and diabetes
prevalence of 34.4%. In the main analysis cohort, TLF was 3.7% at 12 months compared with historical E-ZES
results (TLF  6.5%). The R-ZES met the 3.3% margin of noninferiority (rate difference  2.8%, upper 1-sided
95% confidence interval: 1.3%, p  0.001). The overall TLF rate was 4.7%, and rates of cardiac death, MI, and
TLR were 0.7%, 1.4%, and 2.8%, respectively. The 12-month rate of stent thrombosis was 0.1%.
Conclusions The R-ZES achieved a very low rate of clinical restenosis while maintaining low rates of important clinical safety
events such as death, MI, and stent thrombosis at 1-year follow-up. (The Medtronic RESOLUTE US Clinical Trial [R-US];
NCT00726453) (J Am Coll Cardiol 2011;57:1778–83) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.005Despite the success of drug-eluting stents (DES) in reduc-
ing repeat revascularization procedures via local delivery of
potent antiproliferative drugs from the stent surface, about
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April 26, 2011:1778–83 The RESOLUTE US Trialan important area of clinical investigation, particularly the
avoidance of late stent thrombosis (ST) (4).
The Resolute zotarolimus-eluting coronary stent (R-ZES)
(Medtronic, Santa Rosa, California) is designed using the same
cobalt chromium stent platform and drug as the U.S. Federal
Drug Administration–approved Endeavor zotarolimus-eluting
coronary stent (E-ZES) (Medtronic). The R-ZES utilizes a
new hydrophilic biocompatible polymer that provides ex-
tended release of zotarolimus over approximately 180 days (5).
his longer duration of drug release was designed to improve
revention of restenosis while maintaining low ST rates.
The RESOLUTE US (R-US) trial is a multicenter, pro-
pective trial designed to compare the R-ZES to historical
linical trial data for the E-ZES, while also examining small
essel treatment and a U.S. population with a relatively high
revalence of diabetes mellitus.
ethods
tudy overview and patient population. The R-US trial
esign and methods with device characteristics, study pro-
edures, and prescribed medications have been previously
escribed (6,7). The clinical outcomes of patients treated
ith R-ZES in lesions suitable for 2.25- to 4.0-mm stents
n 1 or 2 vessels were evaluated. To avoid the confounding
ffect of angiography on clinical outcomes, subjects were
ither enrolled with prospective, clinical follow-up only
clinical cohort, n  1,242), or with protocol-specified
ngiographic follow-up in a consecutive series of subjects
t eligible sites (angiographic cohort, n  160). A subset
f the angiographic cohort also received intravascular
ltrasound (IVUS) examination (n  100). A 38-mm
tent length substudy is still enrolling patients.
Clinical Cohort*
N=1242
Main Analysis Cohort
2.5 mm – 3.5 mm stent,
single lesion only
N=1001
Main Analysis Cohort
982 (98.1%) patients 
evaluable at 12 months 
1
e
2.2
1
Figure 1 Patient Disposition
Baseline enrollment and evaluable patients at 12 months for all patients, the mai
*Clinical Cohort includes 241 patients with 2 lesions treated and/or using a 2.25Institutional review boards at all
ites approved the study protocol.
ritten informed consent was ob-
ained from each patient. Major
nclusion criteria included adults
ith clinical evidence of ischemic
eart disease attributable to ste-
otic lesion(s) in de novo native
oronary arteries and planned
reatment of up to 2 lesions located
n separate target vessels. Impor-
ant exclusion criteria included ev-
dence of acute myocardial infarc-
ion (MI) within 72 h of the
rocedure or previous treatment of
he target vessels for restenosis.
nalysis populations. The main
nalysis consisted of patients
rom the clinical cohort (n 
,242) compared with historical
ontrols derived from all trials of
-ZES patients with clinical
ollow-up only (ENDEAVOR II,
NDEAVOR IV, ENDEAVOR
K, and ENDEAVOR II Con-
inued Access trials) (8–10). Be-
ause these E-ZES trials predom-
nantly enrolled patients treated
or a single lesion with 2.5- to
.5-mm stents, the population for
he main analysis of the R-US trial
as further restricted to patients with 2.5- to 3.5-mm stents
ith single-lesion treatment (main analysis cohort, n 
Angiographic  Cohort
N=160
ll Population
8.1%) patients 
le at 12 months
Angiographic  Cohort
150 (93.8%) patients evaluable for
angiography at 8 months
ll Population
 – 4.0 mm stents
atients Enrolled
ysis cohort, and the angiographic cohort.
tent.
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ST  stent thrombosis
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The RESOLUTE US Trial April 26, 2011:1778–831,001). Clinical outcomes were also analyzed for all enrolled
patients.
Endpoints. The primary endpoint of the main analysis
cohort was target lesion failure (TLF), defined as cardiac
death, MI, or clinically-driven target lesion revascular-
ization (TLR) by percutaneous or surgical methods at 12
months. The primary endpoint for the 2.25-mm stent
group was also TLF at 12 months. The primary angio-
graphic endpoint for the 4.0-mm stent group was in-
segment late loss at 8 months. If multiple lesions quali-
fying were treated, an index lesion was selected as
previously described (6).
Definitions. For this trial, all deaths were considered
cardiac unless an unequivocal noncardiac cause could be
established. MI was defined as previously described (6).
TLR was defined as clinically-driven repeat percutaneous
coronary intervention (PCI) of the target lesion or coronary
artery bypass grafting (CABG) including the target vessel.
Target vessel revascularization (TVR) was defined as
clinically-driven repeat PCI or CABG of the target vessel.
All ST events were adjudicated according to Academic
Research Consortium criteria (11).
Data management and core laboratories. All data were
submitted to a central data coordinating facility (Harvard
Clinical Research Institute [HCRI], Boston, Massachu-
setts). An independent clinical events committee (HCRI)
and core laboratories (angiographic: Beth Israel Deaconess
Medical Center, Boston, Massachusetts; IVUS: Cardiovas-
cular Core Analysis Laboratory, Stanford University, Palo
Alto, California) reviewed the relevant primary data.
Statistical analysis. The primary analysis was designed
such that a total of 800 analyzable patients with single
lesions in the main analysis cohort would yield 87% power
to assess the noninferiority of the R-ZES compared with
E-ZES using a noninferiority margin (delta) of 3.3% with
respect to the primary endpoint of TLF. Baseline charac-
teristics that could impact the primary endpoint were
compared between treatment groups, and propensity score
adjustment was used to address imbalances at baseline between
the 2 groups. Variables used to generate the propensity score
are shown in the Online Appendix. The c-index for the
separation of groups is 0.663. A 1-sided upper 95% confi-
dence interval of the treatment difference (R-ZES minus
E-ZES) in TLF rates adjusted for propensity score quintile
was calculated. All statistical analyses were performed by
HCRI using PC SAS for Windows version 9.1 (SAS
Institute, Cary, North Carolina).
Results
Study population. From August 21, 2008, to December
16, 2009, 1,402 patients were enrolled at 116 centers in the
United States (Fig. 1). Diabetes mellitus prevalence was
4% overall (Table 1). The main analysis cohort patients
ad shorter lesions, smaller mean reference vessel diameterRVD), and a higher incidence of diabetes mellitus than
-ZES control patients (Online Table 1).
rimary endpoints. The 12-month rate of TLF for the
ain analysis cohort was 3.7% (36 of 982) compared with
.5% (70 of 1,076) for historical control patients treated
ith the E-ZES (difference, 2.8%; adjusted 1-sided 95%
onfidence interval upper limit, 1.3%; pnoninferiority 
0.001; post-hoc psuperiority  0.002). The Kaplan-Meier
curve for TLF is displayed in Figure 2. The 12-month rates
of cardiac death, MI, and TLR are shown in Figure 3.
Overall clinical outcomes. The 30-day and 12-month
clinical outcomes for the overall study population are shown
in Table 2. The cumulative incidence curves for TLF,
cardiac death and MI, TLR, and definite and probable ST
Baseline Clinical, Lesion,and Procedural CharacteristicsTable 1 Baseline Clin cal, Lesion,and Procedural Characteristics
Characteristic
All Patients
2.25- to 4.0-mm Stents
(n  1,402)
Age, yrs 64.1 10.7
Male 68.3%
Prior MI 21.6%
Prior PCI 32.7%
Prior CABG 8.8%
Diabetes mellitus 34.4%
IDDM 9.6%
Hyperlipidemia 87.7%
Hypertension 84.2%
History of smoking, current 20.9%
Reason for revascularization
Stable angina 56.1%
Unstable angina 41.9%
Recent MI 2.1%
Target lesion coronary artery
Left anterior descending 45.9%
Left circumflex 32.2%
Right 31.2%
Left main 0.6%
Two vessel treatment 10.4%
TIMI flow grade 3 96.7%
RVD, mm 2.59 0.47
Lesion length, mm 13.06 5.88
Minimum lumen diameter, mm 0.77 0.35
% diameter stenosis 70.67 11.52
Type B2/C lesion 75.2%
Procedural results
Post-procedure TIMI flow grade 3 99.7%
Final RVD, mm 2.64 0.48
Final MLD, mm
In stent 2.49 0.43
In segment 2.14 0.46
Final % diameter stenosis
In stent 5.02 8.88
In segment 18.88 8.98
Data are mean  SD or %.
CABG  coronary artery bypass grafting; IDDM  insulin-dependent diabetes mellitus; MI 
myocardial infarction; MLD  minimum lumen diameter; PCI  percutaneous coronary interven-
tion; RVD  reference vessel diameter; TIMI  Thrombolysis In Myocardial Infarction.for the overall population are displayed in Figure 4.
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April 26, 2011:1778–83 The RESOLUTE US TrialThe overall rate of ST was 0.1% (2 of 1,376), and dual
antiplatelet use was 97.0% at 30 days and 93.3% at 12
months. Definite or probable ST was observed only among
patients treated with 2.25-mm stents. This included 1
patient with definite ST who presented with MI and
angiographically confirmed ST on day 32 despite dual
antiplatelet therapy, and 1 patient with probable ST who
was not discharged on aspirin and died of presumed cardiac
causes on day 5.
Angiographic and IVUS outcomes. Mean in-stent late
loss was 0.30  0.54 mm for the angiographic cohort at 8
onths (Table 3). One case of late acquired incomplete
pposition was observed during follow-up IVUS (Table 3).
he 2.25- and 4.0-mm stent groups. Prespecified end-
oints for the 2.25-mm stent group and 4.0-stent group
ere met (2.25-mm group: 12-month TLF, 4.8% (7 of
46); 1-sided 95% confidence interval upper limit, 8.8%;
omparison with a preset performance goal of 20%, p 
.001; 4.0-mm group: TLF, 6.8% (4 of 59); in-segment late
oss, 0.14  0.44 mm; psuperiority  0.001 compared with
.65  0.62 mm from historical bare-metal stent control).
Figure 2 Cumulative Incidence of TLF: Main Analysis Cohort
Cumulative incidence of 12-month target lesion failure (TLF) in patients undergoing
Figure 3 12-Month TLF, Cardiac Death, MI, and TLR: Main Ana
Twelve-month target lesion failure (TLF) comprising cardiac death, myocardial infarctioiabetic group. Three hundred seventy-four patients with
.5- to 3.5-mm stents and diabetes mellitus from the
linical cohort were included in a pre-specified diabetic
nalysis. The rate of 12-month TLF was 4.3% (cardiac
eath, 0.5%; MI, 0.8%; TLR, 3.0%).
iscussion
his study met its primary endpoint of noninferiority of the
-ZES main analysis cohort compared with the E-ZES
ontrol group. In this cohort (2.5- to 3.5-mm stents in
ingle lesions; 71% of overall patients), the R-ZES signifi-
antly lowered TLF by 43% (6.5% to 3.7%, psuperiority 
.002), including a low rate of TLR (2.0%). These findings
ere consistent with the overall clinical outcomes when
atients with 2.25-mm stents, 4.0-mm stents, and 2-vessel
reatment were also included. This favorable result was
chieved despite the higher proportion of diabetic patients
34%) than prior studies and the inclusion of patients
eceiving 2.25-mm stents (11%), wherein both of these
igh-risk subsets also had favorable clinical outcomes.
e-lesion treatment with 2.5- to 3.5-mm stents.
Cohort
and target lesion revascularization (TLR) for the main analysis cohort (n  982).singllysis
n (MI),
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The RESOLUTE US Trial April 26, 2011:1778–83Compared with the 30-day ST rate of 0.8% observed in
the RESOLUTE All Comers trial (12), the ST rate in this
U.S. trial is 0.1% (2/1,376). Both of these events occurred in
2.25-mm stents, confirming published observations that
small vessels may confer additional risk even with bare-
metal stents (13). The absence of ST in patients with stents
2.5 mm is notable, though this is achieved with dual
antiplatelet therapy (93.3% at 12 months), and longer-term
follow-up is ongoing. Recent randomized and registry
Clinical Outcomes at 30 Days and 12 Monthsfor All Patients (2.25- to 4.0-mm Stents)Table 2 Clinical Outcomes at 30 Days and 12 Monthsfor All Patients (2.25- to 4.0-mm Stents)
Outcome
30 Days
(n  1,398)
12 Months
(n  1,376)
TLF 1.4% (20) 4.7% (65)
Death 0.1% (1) 1.3% (18)
Cardiac 0.1% (1) 0.7% (9)
Noncardiac 0.0% (0) 0.7% (9)
Myocardial Infarction 1.2% (17) 1.4% (19)
Q-wave 0.1% (1) 0.1% (2)
Non–Q-wave 1.1% (16) 1.2% (17)
Clinically-driven TLR 0.1% (2) 2.8% (39)
Clinically-driven TVR 0.4% (5) 4.6% (63)
Stent thrombosis (ARC
definite  probable)
0.1% (1) 0.1% (2)
Early (30 days) 0.1% (1) 0.1% (1)*
Late (30 and 360 days) n/a 0.1% (1)†
Data are % (n). *Probable stent thrombosis; †definite stent thrombosis.
ARC  Academic Research Consortium; TLF  target lesion failure; TLR  target lesion
revascularization; TVR  target vessel revascularization.
Figure 4 Cumulative Incidence of TLF, Cardiac Death plus MI,
Cumulative incidence of 12-month target lesion failure (TLF) (A), cardiac death an
and definite and probable stent thrombosis (D) for the overall population.studies have extended the observations regarding the
R-ZES to include some patient populations excluded from
this trial, such as acute or recent MI, and more complex
coronary anatomy (12,14).
Study limitations. Randomized studies are the gold stan-
dard for comparison of treatments, as these methods prevent
and Stent Thrombosis: Overall Population
ardial infarction (MI) (B), target lesion revascularization (TLR) (C),
Angiographic and IVUS Measuresat 8 Mont s for Angiographic CohortTable 3 Angiographic and IVUS Measuresat 8 Months for Angiographic Cohort
Variable
2.25 to 4.0 mm
(n  153 Lesions)
Angiography
Reference vessel diameter, mm 2.77 0.58
Minimum lumen diameter, mm
In stent 2.40 0.78
In segment 2.12 0.70
Diameter stenosis, % of lumen diameter
In stent 13.64 22.25
In segment 24.25 18.15
Binary restenosis rate
In stent 9.2%
In segment 9.8%
Late loss, mm
In stent 0.30 0.54
In segment 0.20 0.43
IVUS
Late acquired incomplete apposition 1.7% (1/60)
Percent volume obstruction 5.34 5.97 (63)
Data are mean  SD or %.
IVUS  intravascular ultrasound.TLR,
d myoc
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April 26, 2011:1778–83 The RESOLUTE US Trialimportant sources of potential bias. Although R-US uses a
single-cohort observational design, care was taken to min-
imize bias and maintain the same standards for endpoint
ascertainment as prior approval studies to which these data
would be compared. Patients with identical inclusion crite-
ria formed the comparator groups. Endpoint definition,
ascertainment, and adjudication were performed with the
same methods. Finally, because the study population was
more complex than the comparative cohort, the primary
study hypothesis testing was performed with propensity
score adjustment. These methods allowed a high degree of
reliability of the data and analysis to ensure prevention of
potential bias.
Conclusions
Although not a randomized clinical study, the R-US trial
shows the R-ZES to be highly efficacious even in challeng-
ing patients with diabetes mellitus and small-size stents,
with a low incidence of stent thrombosis. This is the first
study, to our knowledge, to evaluate the direct impact of
drug elution characteristics on clinical outcomes, using
identical drug-eluting stents except for a new polymer that
extends drug elution.
Acknowledgments
The authors thank Manuela Negoita, MD, and Judith
Jaeger, Medtronic, Inc., for contributions to study manage-
ment, Minglei Liu, PhD, Medtronic, Inc., for statistical
review, and Denise Jones, BSN, and Colleen Gilbert,
PharmD, for editorial support.
Reprint requests and correspondence: Dr. Laura Mauri, Divi-
sion of Cardiovascular Medicine, Department of Medicine,
Brigham and Women’s Hospital, 75 Francis Street, Boston,
Massachusetts 02115. E-mail: lmauri1@partners.org.
REFERENCES
1. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-
eluting stent in patients with coronary artery disease. N Engl J Med
2004;350:221–31.
2. Mauri, L, Massaro JM, Jiang S, et al. Long-term clinical outcomes
with zotarolimus-eluting versus bare-metal stents. J Am Coll Cardiol
Intv 2010;3:1240–9.3. Stolker JM, Kennedy KF, Lindsey JB, et al. Predicting restenosis of
drug-eluting stents placed in real-world clinical practice: derivation
and validation of a risk model from the EVENT registry. Circ
Cardiovasc Interv 2010;3:327–34.
4. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip
DE. Stent thrombosis in randomized clinical trials of drug-eluting
stents. N Engl J Med 2007;356:1020–9.
5. Udipi K, Chen M, Cheng P, et al. Development of a novel biocom-
patible polymer system for extended drug release in a next-generation
drug-eluting stent. J Biomed Mater Res A 2008;85:1064–71.
6. Mauri L, Leon MB, Yeung AC, Negoita M, Keyes MJ, Massaro JM.
Rationale and Design of the Clinical Evaluation of the Resolute
Zotarolimus-Eluting Coronary Stent System in the Treatment of De
Novo Lesions in Native Coronary Arteries (the RESOLUTE US
clinical trial). Am Heart J 2011. In press.
7. Meredith I, Worthley S, Whitbourn R, et al. Clinical and angio-
graphic results with the next-generation Resolute stent system: a
prospective, multicenter, first-in-human trial. J Am Coll Cardiol Intv
2009;2:977–85.
8. Fajadet J, Wijns W, Laarman GJ, et al., for the ENDEAVOR II
Investigators. Randomized, double-blind, multicenter study of the
Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent
for treatment of native coronary artery lesions: clinical and angio-
graphic results of the ENDEAVOR II trial. Circulation 2006;114:
798–806.
9. Leon M, Mauri L, Popma JJ, et al., for the ENDEAVOR IV
Investigators. A randomized comparison of the Endeavor zotarolimus-
eluting stent versus the TAXUS paclitaxel-eluting stent in de novo
native coronary lesions: 12-month outcomes from the ENDEAVOR
IV Trial. J Am Coll Cardiol 2010;55:543–54.
10. Schultheiss HP, Grube E, Kuck KH, et al., Endeavor II Continued
Access Investigators. Safety of direct stenting with the Endeavor stent:
results of the Endeavor II continued access registry. EuroIntervention
2007;3:76–81.
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in
coronary stent trials: a case for standardized definitions. Circulation
2007;115:2344–51.
12. Serruys PW, Silber S, Garg S. et al. Comparison of zotarolimus-
eluting and everolimus-eluting coronary stents. N Engl J Med 2010;
363:136–46.
13. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern
era: a pooled analysis of multicenter coronary stent clinical trials.
Circulation 2001;103:1967–71.
14. Widimsky P, Belardi JA, Neumann F-J. TCT-282: one year outcomes
of patients with Resolute zotarolimus-eluting stent: results of the
RESOLUTE International Registry (abstr). J Am Coll Cardiol
2010;56:B65.
Key Words: coronary artery disease y drug-eluting stent y
revascularization y zotarolimus.
APPENDIX
For a supplemental table and an expanded Methods section,
please see the online version of this article.
